Purpose: The aim of this study was to compare sleep problem categories of children with mental retardation without general medical condition (MR-GMC), children with MR co-occurring with GMC (MR+GMC), siblings of the MR children, and the general population.
Method: This is the first study which separates MR children with GMC and those without GMC. The Children's Sleep Habits Questionnaire was completed by their parents to assess their children's sleep practices and behaviors such as the child's sleeping habits, sleeping arrangements, sleep anxiety, night wakening, parasomnias, and daytime sleepiness.
Results: The clusters of bedtime resistance and sleep duration, wake up, parasomnia, sleep anxiety, and other problem categories were not different between MR children without GMC and the other two control groups of general population and siblings group. Parasomnia and other problem categories were more impaired in MR+GMC group than the three groups of MR-GMC, general population, and siblings.
Conclusions: The lack of difference between the MR+GMC group and those in the control groups may suggest that medical predisposing factors may contribute to an increased rate of sleep problems in MR children, rather than their MR as a cause of sleep problems. Probably, management of the accompanying medical conditions of the MR children would improve their sleep; in other words, the sleep difficulties of the children with MR are more related to their general medical problems rather than their MR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11325-009-0312-0 | DOI Listing |
Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: The ability to monitor cognitive trajectories over the course of trials can provide valuable insights into treatment efficacy. However, existing trial methods are limited in monitoring cognition in real-time and at high frequencies. Gameplay-based assessments hold promise as complementary cognitive tools.
View Article and Find Full Text PDFBackground: Differences in patient characteristics across geographical regions may result in heterogeneity in clinical trial populations. evoke (NCT04777396) and evoke+ (NCT04777409) are two phase 3, multinational, randomised trials investigating semaglutide versus placebo in individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease (AD) (early AD). We present baseline characteristics across the geographical regions in evoke/evoke+.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Preclinical Alzheimer's disease (AD) trials can involve multiple years of follow-up and burdensome procedures for older individuals. Optimizing the design and conduct of these trials requires input from participants and their families. Since 2020, the Alzheimer's Clinical Trials Consortium (ACTC) Research Participant Advisory Board has provided input on study attributes including: participant and study partner compensation, consent language, and result communication tools.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!